Cerebrospinal fluid concentrations of quinupristin-dalfopristin in a patient with vancomycin-resistant Enterococcus faecium [correction of faecalis] ventriculitis.
A 44-year-old man was treated successfully for vancomycin-resistant Enterococcus faecium (VREF) ventriculitis with intrathecal quinupristin-dalfopristin 1 mg, 2 mg, and 4 mg, and other intravenous antibiotics. Cerebrospinal fluid samples were collected before and after the 1-mg and 2-mg doses to determine the concentrations of quinupristin-dalfopristin and its active metabolites. Concentrations were above the minimum inhibitory concentration for VREF immediately after unclamping the extraventricular drain and were quantifiable for at least 7 hours.
Garey
K W
KW
University of Illinois at Chicago, 60612, USA.
Tesoro
E
E
Muggia
V
V
Pasquier
O
O
Rodvold
K A
KA
D000328:Adult; D002557:Cerebrospinal Fluid Shunts / Q000009:adverse effects; D004660:Encephalitis / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000209:etiology; D013293:Enterococcus faecalis / Q000187:drug effects; D016908:Gram-Positive Bacterial Infections / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests / Q000592:standards; D020713:Vancomycin Resistance; D014769:Virginiamycin / Q000008:administration & dosage / Q000134:cerebrospinal fluid*
D014769:Virginiamycin; C062940:quinupristin-dalfopristin